Free Trial
→ My prediction for December 8th (From Behind the Markets) (Ad)tc pixel
NASDAQ:PULM

Pulmatrix Q3 2026 Earnings Date & Estimates

Pulmatrix logo
$1.35 -0.01 (-0.66%)
As of 03:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pulmatrix is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. The conference call is scheduled for November 16, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Pulmatrix in Q3 2026

Pulmatrix is expected to post earnings of -$2.00 per share on revenue of $1.53 million. In the same quarter a year earlier Pulmatrix reported -$0.24 per share. Pulmatrix last reported on August 13, 2026, posting -$0.29 per share and beating the -$2.00 consensus estimate.

Consensus Estimates

Consensus EPS
-$2.00
Expected Revenue
$1.53 million
Prior-Year EPS
-$0.24

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.29 (Beat by +$1.71)

Prepare for the Q3 2026 Call

Pulmatrix Q3 2026 Earnings FAQ

Pulmatrix (NASDAQ:PULM) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Pulmatrix's Q3 2026 earnings conference call is scheduled for Monday, November 16, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Pulmatrix to post earnings of -$2.00 per share for Q3 2026.

The consensus revenue estimate for Pulmatrix is $1.53 million for Q3 2026.

Pulmatrix Earnings Headlines

Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
November 9 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3398364/0/en/eos-senolytix-s-ptc-2105-reduced-semaglutide-associated-lean-mass-loss-in-aged-mice-data-to-be-presented-at-19th-sarcopenia-cachexia-wasting-disorders-international-conference.html
Pulmatrix (PULM) Projected to Post Quarterly Earnings on Thursday
November 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31177906
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
November 10 at 1:00 AM  |  Porter & Company (Ad)
Eos SENOLYTIX Reports Preserved Motor Function In Aged Rats With PTC-2105; Stock Down
October 30, 2026  |  rttnews.comhttps://www.rttnews.com/3706597/eos-senolytix-reports-preserved-motor-function-in-aged-rats-with-ptc-2105-stock-down.aspx
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
October 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/30/3392194/0/en/eos-senolytix-reports-interim-data-showing-preserved-physical-function-with-mitoxcel-geropeptide-ptc-2105-in-a-second-species-aged-rat-study.html
Pulmatrix, Inc. stockholders approve merger-related proposals and reverse stock split
October 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/pulmatrix-inc-stockholders-approve-merger-related-proposals-and-reverse-stock-split/ar-AA2gbGBJ
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other diseases. The company’s research is based on its iSPERSE dry-powder delivery technology, which is designed to enable efficient administration of pharmaceutical compounds directly to the lungs.

Pulmatrix’s pipeline has included PUR1900, an inhaled formulation of itraconazole being developed for respiratory fungal infections, including allergic bronchopulmonary aspergillosis. The company has also advanced PUR3100, an inhaled formulation of dihydroergotamine intended for the potential acute treatment of migraine. Development programs and indications may change as clinical and regulatory activities progress.

Based in Lexington, Massachusetts, Pulmatrix has historically concentrated on pharmaceutical development rather than commercial product sales. Its operations have primarily involved research, clinical testing and the potential partnering or licensing of inhaled medicines for patients in the United States and other international markets.

View Pulmatrix Profile
Earnings Tools